Literature DB >> 23400721

Sporadic Jakob-Creutzfeldt disease presenting as primary progressive aphasia.

David Y Johnson1, Diana L Dunkelberger, Maya Henry, Aissatou Haman, Michael D Greicius, Katherine Wong, Stephen J DeArmond, Bruce L Miller, Maria Luisa Gorno-Tempini, Michael D Geschwind.   

Abstract

OBJECTIVE: To report the clinical, neuropsychological, linguistic, imaging, and neuropathological features of a unique case of sporadic Jakob-Creutzfeldt disease in which the patient presented with a logopenic variant of primary progressive aphasia.
DESIGN: Case report.
SETTING: Large referral center for atypical memory and aging disorders, particularly Jakob-Creutzfeldt disease. PATIENT: Patient presenting with logopenic variant primary progressive aphasia initially thought to be due to Alzheimer disease.
RESULTS: Despite the long, slow 3.5-year course, the patient was shown to have pathology-proven sporadic Jakob-Creutzfeldt disease.
CONCLUSIONS: These findings expand the differential of primary progressive aphasia to include prion disease.

Entities:  

Mesh:

Year:  2013        PMID: 23400721      PMCID: PMC4365870          DOI: 10.1001/2013.jamaneurol.139

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  19 in total

1.  The 14-3-3 gene expression specificity in response to stress is promoter-dependent.

Authors:  Anna Aksamit; Alina Korobczak; Jacek Skala; Marcin Lukaszewicz; Jan Szopa
Journal:  Plant Cell Physiol       Date:  2005-08-04       Impact factor: 4.927

2.  A 54-year-old man with slowness of movement and confusion.

Authors:  Michael D Geschwind; Keith A Josephs; Joseph E Parisi; B Mark Keegan
Journal:  Neurology       Date:  2007-11-06       Impact factor: 9.910

3.  Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease.

Authors:  S J Collins; P Sanchez-Juan; C L Masters; G M Klug; C van Duijn; A Poleggi; M Pocchiari; S Almonti; N Cuadrado-Corrales; J de Pedro-Cuesta; H Budka; E Gelpi; M Glatzel; M Tolnay; E Hewer; I Zerr; U Heinemann; H A Kretszchmar; G H Jansen; E Olsen; E Mitrova; A Alpérovitch; J-P Brandel; J Mackenzie; K Murray; R G Will
Journal:  Brain       Date:  2006-07-01       Impact factor: 13.501

4.  Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type.

Authors:  J C Morris
Journal:  Int Psychogeriatr       Date:  1997       Impact factor: 3.878

Review 5.  Rapidly progressive dementia.

Authors:  Michael D Geschwind; Huidy Shu; Aissa Haman; James J Sejvar; Bruce L Miller
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

6.  Clinical heterogeneity and unusual presentations of Creutzfeldt-Jakob disease in Jewish patients with the PRNP codon 200 mutation.

Authors:  J Chapman; P Brown; L G Goldfarb; A Arlazoroff; D C Gajdusek; A D Korczyn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-10       Impact factor: 10.154

Review 7.  Rapidly progressive dementia.

Authors:  Michael D Geschwind; Aissa Haman; Bruce L Miller
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

8.  Creutzfeldt-Jakob disease presenting as isolated aphasia.

Authors:  A M Mandell; M P Alexander; S Carpenter
Journal:  Neurology       Date:  1989-01       Impact factor: 9.910

9.  Genes contributing to prion pathogenesis.

Authors:  Gültekin Tamgüney; Kurt Giles; David V Glidden; Pierre Lessard; Holger Wille; Patrick Tremblay; Darlene F Groth; Fruma Yehiely; Carsten Korth; Richard C Moore; Jörg Tatzelt; Eric Rubinstein; Claude Boucheix; Xiaoping Yang; Pamela Stanley; Michael P Lisanti; Raymond A Dwek; Pauline M Rudd; Jackob Moskovitz; Charles J Epstein; Tracey Dawson Cruz; William A Kuziel; Nobuyo Maeda; Jan Sap; Karen Hsiao Ashe; George A Carlson; Ina Tesseur; Tony Wyss-Coray; Lennart Mucke; Karl H Weisgraber; Robert W Mahley; Fred E Cohen; Stanley B Prusiner
Journal:  J Gen Virol       Date:  2008-07       Impact factor: 3.891

10.  Creutzfeldt-Jakob disease with long duration and panencephalopathic lesions: molecular analysis of one case.

Authors:  I Ghorayeb; C Series; P Parchi; B Sawan; S Guez; J L Laplanche; S Capellari; P Gambetti; C Vital
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

View more
  6 in total

Review 1.  Towards a clearer definition of logopenic progressive aphasia.

Authors:  Cristian E Leyton; John R Hodges
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

2.  Case 1-2017. A 70-Year-Old Woman with Gradually Progressive Loss of Language.

Authors:  M-Marsel Mesulam; Bradford C Dickerson; Janet C Sherman; Daisy Hochberg; R Gilberto Gonzalez; Keith A Johnson; Matthew P Frosch
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

3.  Atypical Alzheimer's disease phenotypes with normal or borderline PET biomarker profiles.

Authors:  Neha Atulkumar Singh; Jonathan Graff-Radford; Mary M Machulda; Christopher G Schwarz; Matthew C Baker; Rosa Rademakers; Nilufer Ertekin-Taner; Val J Lowe; Keith A Josephs; Jennifer L Whitwell
Journal:  J Neurol       Date:  2022-08-24       Impact factor: 6.682

4.  Related or not? Development of spontaneous Creutzfeldt-Jakob disease in a patient with chronic, well-controlled HIV: A case report and review of the literature.

Authors:  M-Alain Babi; Bryan D Kraft; Sweta Sengupta; Haley Peterson; Ryan Orgel; Zachary Wegermann; Njira L Lugogo; Matthew W Luedke
Journal:  SAGE Open Med Case Rep       Date:  2016-10-13

5.  Creutzfeldt-Jakob Disease with a Five-Year Clinical Course, Multicentric Cerebellar Prion Plaques and Prior History of Biopsy-Proven Primary Angiitis of the Central Nervous System: A Case for Iatrogenic Exposure?

Authors:  Kristina Jeon; Jeffrey T Joseph; Gerard H Jansen; Anne Peterson; J David Knox; Valerie L Sim
Journal:  Viruses       Date:  2020-12-08       Impact factor: 5.048

6.  Erythrocyte Indices in Creutzfeldt-Jakob Disease Predict Survival Time.

Authors:  Yu Kong; Zhongyun Chen; Jing Zhang; Liyong Wu
Journal:  Front Neurol       Date:  2022-02-14       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.